Veloxis Announces Scientific Publication of Phase II Study Demonstrating Conversion from Twice-Daily Tacrolimus to Once-Daily Envarsus® in Liver Transplant Patients
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - April 28, 2014 Category: Pharmaceuticals Source Type: news
Tacrolimus Eye Drops for Refractory Allergic Ocular DiseasesTacrolimus Eye Drops for Refractory Allergic Ocular Diseases
Use of tacrolimus 0.1% eye drops is associated with significant improvement of refractory allergic conjunctivitis with proliferative lesions and/or corneal involvement, according to an observational study from Japan. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - April 22, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news
FDA awards $2.25M grant to study immunosuppresive drug in high-risk patients
(University of Cincinnati Academic Health Center) University of Cincinnati Research Professor Rita Alloway, PharmD, has been awarded a $2.25 million grant from the U.S. Food and Drug Administration to study the safety and efficacy of the generic immunosuppressive drug tacrolimus in transplant patients. As a "cornerstone drug" in post-transplant immunosuppression, tacrolimus is used to lower the risk of organ rejection -- these studies are aimed to address public concerns regarding the use of new generic formulations in high-risk transplant recipients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 7, 2013 Category: Global & Universal Source Type: news
Prophylaxis of fungal infections in liver transplant patients
New data presented at the 16th Congress of the European Society for Organ Transplantation (ESOT) demonstrate that in liver transplant patients, initiating ADVAGRAF™ prolonged-release capsules (tacrolimus) therapy immediately post transplant, at a dose 25% lower than the upper recommended limit,(8) in combination with basiliximab, results in significantly better renal function and a lower incidence of acute organ rejection when compared with standard dose ADVAGRAF therapy.(9) Furthermore, delaying the introduction of ADVAGRAF post transplant gives no additional advantage in terms of renal function.(9) (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 12, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Transplantation Latest News Source Type: news
Tacrolimus Dose in Pediatric Liver TransplantationTacrolimus Dose in Pediatric Liver Transplantation
Tacrolimus has become the mainstay of immunosuppressive treatment in pediatric liver transplantation. How does the CYP3A5 genotype effect tacrolimus dose requirements? Pharmacogenomics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 8, 2013 Category: Consumer Health News Tags: Transplantation Journal Article Source Type: news
Astagraf XL (Tacrolimus Extended-release Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 2, 2013 Category: Drugs & Pharmacology Source Type: news
Long-Release Tacrolimus Wins FDA Nod
(MedPage Today) -- An extended-release formulation of tacrolimus (Astagraf XL) for preventing kidney transplant rejection has been approved by the FDA, its manufacturer said. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 22, 2013 Category: Primary Care Source Type: news
Roche launches new tests for monitoring transplant patients on immunosuppressive therapy
Roche today announced the global launch (except US) of two new highly sensitive therapeutic drug monitoring tests for the immunosuppressant medicines tacrolimus and cyclosporine. The new Elecsys Tacrolimus and Cyclosporine tests provide healthcare professionals with more accurate and reliable results. They are made for use on Roche’s cobas modular analysers, thus also supporting enhanced workflow and efficiency in medical laboratories. (Source: Roche Investor Update)
Source: Roche Investor Update - July 19, 2013 Category: Pharmaceuticals Source Type: news
Roche launches new tests for monitoring transplant patients on immunosuppressive therapy
Roche today announced the global launch (except US) of two new highly sensitive therapeutic drug monitoring tests for the immunosuppressant medicines tacrolimus and cyclosporine. The new Elecsys Tacrolimus and Cyclosporine tests provide healthcare professionals with more accurate and reliable results. They are made for use on Roche’s cobas modular analysers, thus also supporting enhanced workflow and efficiency in medical laboratories. (Source: Roche Media News)
Source: Roche Media News - July 19, 2013 Category: Pharmaceuticals Source Type: news
New Automated Immunosuppressive Drug Assays Improve Therapeutic Drug Monitoring for Transplant Patients
For the first time, certain immunosuppressive drug (ISD) assays can now be performed automatically on cobas® modular platforms, allowing laboratories to consolidate testing for a wide range of transplant testing/monitoring assays onto a single platform. The new Roche automated assays for tacrolimus and cyclosporine will enhance therapeutic drug monitoring (TDM) of transplant recipients by providing the consistency and accuracy of an automated assay, while enhancing workflows, auditing and reporting capabilities in the laboratory. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - July 2, 2013 Category: Pharmaceuticals Source Type: news
Infant Breast Milk Exposure to Tacrolimus Negligible Infant Breast Milk Exposure to Tacrolimus Negligible
A new study has found that infant exposure to tacrolimus during breast-feeding is minimal and blood levels of the drug are comparable to those found in bottle-fed infants. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2013 Category: Consumer Health News Tags: Pediatrics News Source Type: news
Tacrolimus breast milk transfer concerns allayed
Breastfeeding mothers taking tacrolimus do not pass the immunosuppressant on to their babies when breastfeeding, study results show. (Source: MedWire News - Ob/Gyn)
Source: MedWire News - Ob/Gyn - January 30, 2013 Category: OBGYN Source Type: news
Tacrolimus breast milk transfer concerns allayed
Breastfeeding mothers taking tacrolimus do not pass the immunosuppressant on to their babies when breastfeeding, study results show. (Source: MedWire News - Pediatrics)
Source: MedWire News - Pediatrics - January 29, 2013 Category: Pediatrics Source Type: news
Mothers Taking Immunosuppressant Drug Ok To Breast Feed
Women taking the immunosuppressant tacrolimus can rest assured that breast feeding will not elevate their babies' exposure to the drug, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). The findings are good news for young women who have received an organ transplant in the past or who are taking the drug for other reasons... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 28, 2013 Category: Consumer Health News Tags: Women's Health / Gynecology Source Type: news
Breastfeeding OK for mothers taking immunosuppressant drug, study suggests
Women taking the immunosuppressant tacrolimus can rest assured that breast feeding will not elevate their babies' exposure to the drug, according to a new study. The findings are good news for young women who have received an organ transplant in the past or who are taking the drug for other reasons. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 24, 2013 Category: Science Source Type: news
